FDA Investigator

Jie He

Latest inspection on record: Shanghai, China, May 2026 · records back to 2012

BiologicsHuman Drugs

FDA inspection record · Last updated July 12, 2026

Overview

  • 21 inspections across 20 sites are on record.
  • 5 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2026-05-20.

At a glance

Inspections

21

Sites

20

Observations

5

Career since

Jul 2012

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Shanghai Henlius Biopharmaceuticals Co., Ltd.20 May 2026Human DrugsOn file
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (FDF Site)15 Dec 2025Human DrugsOn file
Eli Lilly & Company20 May 2025Human DrugsView 483 →
FUJIFILM Diosynth Biotechnologies Texas, LLC11 Mar 2025Human DrugsOn file
Allergan Pharmaceuticals Ireland30 Jan 2025Human DrugsOn file

Sites inspected

Eli Lilly & CompanyIndianapolis, United States1 insp.
FUJIFILM Diosynth Biotechnologies Texas, LLCCollege Station, United States1 insp.
Allergan Pharmaceuticals IrelandWestport, Ireland1 insp.

Co-investigators

Investigators who share inspections with this person.

Zhong Li2 shared
Carl A Perez2 shared
Randa Melhem2 shared
Xiaoshi Wang1 shared
Scott D Mcgrew1 shared

Full investigator report

Get the verbatim findings behind Jie He's 5 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site